Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-Aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3 H)-yl]-1-(methylamino)butan-2- ols (WYE-103231)

Journal of Medicinal Chemistry

Volumn 53, Issue 11, 2010, Pages 4511-4521

  O'Neill, David J ^a   Adedoyin, Adedayo ^a   Alfinito, Peter D ^a   Bray, Jenifer A ^a   Cosmi, Scott ^a   Deecher, Darlene C ^a   Fensome, Andrew ^a   Harrison, Jim ^b   Leventhal, Liza ^b   Mann, Charles ^a   McComas, Casey C ^a   Sullivan, Nicole R ^b   Spangler, Taylor B ^b   Uveges, Albert J ^b   Trybulski, Eugene J ^a   Whiteside, Garth T ^b   Zhang, Puwen ^a  

^a PFIZER INC   (United States)

^b Neuroscience   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 4 [3 (2 FLUOROPHENYL) 2,2 DIOXIDO 2,1,3 BENZOTHIADIAZOL 1(3H) YL] 1 (METHYLAMINO)BUTAN 2 OL; ATOMOXETINE; DESIPRAMINE; DOPAMINE TRANSPORTER; GABAPENTIN; MAZINDOL; MORPHINE; NISOXETINE; NORADRENALIN TRANSPORTER; NORADRENALIN UPTAKE INHIBITOR; REBOXETINE; SEROTONIN TRANSPORTER; TRITIUM; UNCLASSIFIED DRUG; WYE 103231;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; ATTENTION DEFICIT DISORDER; CHO CELL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; FLUSHING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOT PLATE TEST; HYPERALGESIA; LIVER MICROSOME; MAJOR DEPRESSION; MALE; MEMBRANE BINDING; NERVE LIGATION; NEUROPATHIC PAIN; NEUROPHARMACOLOGY; NONHUMAN; NORADRENALIN UPTAKE; OVARIECTOMY; RAT; SPINAL NERVE; THERMOREGULATION;

ANIMALS; CELL LINE; CYCLIC S-OXIDES; DRUG DISCOVERY; FEMALE; HUMANS; MALE; NEUROTRANSMITTER UPTAKE INHIBITORS; NOREPINEPHRINE; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; THIADIAZOLES;

EID: 77953213135     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm100053t     Document Type: Article

References (31)

1. Gether, U.; Andersen, P. H.; Larsson, O. M.; Schousboe, A. Neurotransmitter transporters: molecular function of important drug targets Trends Pharmacol. Sci. 2006, 27, 375-383
2. Iversen, L. Neurotransmitter transporters and their impact on the development of psychopharmacology Br. J. Pharmacol. 2006, 147, S82-S88
3. Babu, R. P. K.; Maita, S. M. Norepinephrine Reuptake Inhibitors for Depression, ADHD and other Neuropsychiatric Disorders Heterocycles 2006, 69, 539-567
4. Walter, M. W. Monoamine reuptake inhibitors: highlights of recent research developments Drug Dev. Res. 2005, 65 (3) 97-118
5. Hajos, M.; Fleishaker, J. C.; Filipiak-Reisner, J. K.; Brown, M. T.; Wong, E. H. F. The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile CNS Drug Rev. 2004, 10 (1) 23-44
6. Kratochvil, C. J.; Vaughan, B. S.; Daughton, J. M.; Mayfield-Jorgensen, M. L.; Burke, W. J. Atomoxetine in the treatment of attention deficit hyperactivity disorder Expert Rev. Neurother. 2004, 4 (4) 601-611
7. Berigan, T. Use of atomoxetine adjunctively in fibromyalgia syndrome Can. J. Psychiatry 2004, 49, 499-500
8. Krell, H. V.; Leuchter, A. F.; Cook, I. A.; Abrams, M. Evaluation of reboxetine, a noradrenergic antidepressant, for the treatment of fibromyalgia and chronic low back pain Psychosomatics 2005, 46, 379-384
9. Mahaney, P. E.; Gavrin, L. K.; Trybulski, E.; Stack, G. P.; Vu, A. T.; Cohn, S. T.; Fei, Y.; Belardi, J. K.; Santilli, A. A.; Sabatucci, J. P.; Leiter, J.; Johnston, G. H.; Bray, J. A.; Burroughs, K. D.; Cosmi, S. A.; Leventhal, L.; Koury Elizabeth, J.; Zhang, Y.; Mugford, C. A.; Ho, D. M.; Rosezweig-Lipson, S. J.; Platt, B.; Smith, V. A.; Deecher, D. C. Structure-Activity Relationships of the Cycloalkanol Ethylamine Scaffold: Discovery of Selective Norepinephrine Reuptake Inhibitors J. Med. Chem. 2008, 51, 4038-4049
10. Zhang, P.; Terefenko, E. A.; Bray, J.; Deecher, D.; Fensome, A.; Harrison, J.; Kim, C.; Koury, E.; Mark, L.; McComas, C. C.; Mugford, C. A.; Trybulski, E. J.; Vu, A. T.; Whiteside, G. T.; Mahaney, P. E. 1-or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2 H-benzimidazol-2-ones: Potent, Selective, and Orally Efficacious Norepinephrine Reuptake Inhibitors J. Med. Chem. 2009, 52 (18) 5703-5711
11. McComas, C. C.; Vu, A. T.; Mahaney, P. E.; Cohn, S. T.; Fensome, A.; Marella, M. A.; Nogle, L.; Trybulski, E. J.; Ye, F.; Zhang, P.; Alfinito, P.; Bray, J.; Johnston, G.; Koury, E.; Deecher, D. C. Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: a new class of selective norepinephrine reuptake inhibitors Bioorg. Med. Chem. Lett. 2008, 18, 4929-4931
12. This work shall be disclosed in a separate communication.
13. Cruciani, G.; Carosati, E.; De Boeck, B.; Ethirajulu, K.; Mackie, C.; Howe, T.; Vianello, R. MetaSite: Understanding Metabolism in Human Cytochromes from the Perspective of the Chemist J. Med. Chem. 2005, 48, 6970-6979
14. Di, L.; Kerns, E. H.; Ma, X. J.; Huang, Y.; Carter, G. T. Applications of high throughput microsomal stability assay in drug discovery Comb. Chem. High Throughput Screening 2008, 11 (6) 469-476
15. This was used as a screening assay (n of 1) to rank compounds and assess their potential for further characterization.
16. Gleeson, M. P. Generation of a Set of Simple, Interpretable ADMET Rules of Thumb J. Med. Chem. 2008, 51 (4) 817-834
17. Holbrook, M.; Malik, M.; Shah, R. R.; Valentin, J.-P. Drug induced shortening of the QT/QTc interval: An emerging safety issue warranting further modelling and evaluation in drug research and development? J. Pharmacol. Toxicol. Methods 2009, 59 (1) 21-28
18. Experimental protocols for in vivo p K work discussed was reported in: Gavrin, L. K.; Mahaney, P. E.; Jenkins, D.; Nogle, L. M.; Mugford, C. A.; Huselton, C.; Leiter, J.; Johnston, G. H.; Bray, J. A.; Burroughs, K. D.; Cosmi, S. A.; Alfinito, P.; Ho, D. M.; Deecher, D. C.; Trybulski, E. J., Discovery of WAY-260022, a Potent and Selective Inhibitor of the Norepinephrine Transporter. ACS Med. Chem. Lett. 2010, DOI: 10.1021/ml100009p.
19. McEwen, B. S.; Alves, S. E. Estrogen actions in the central nervous system Endocr. Rev. 1999, 20 (3) 279-307
20. Riedel, W.; Dorward, P. K.; Korner, P. I. Central adrenoceptors modify hypothalamic thermoregulatory patterns of autonomic activity in conscious rabbits J. Auton. Nerv. Syst. 1981, 3, 525-533
21. Rintamaki, H.; Lahti, H.; Hissa, R. Feather position of the pigeon after intrahypothalamic injections of noradrenaline, 5-hydroxytryptamine and carbachol Experientia 1981, 37, 1173-1175
22. Deecher, D. C.; Alfinito, P. D.; Leventhal, L.; Cosmi, S.; Johnston, G. H.; Merchenthaler, I.; Winneker, R. Alleviation of thermoregulatory dysfunction with the new serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized rodent models Endocrinology 2007, 148, 1376-1383
23. Loprinzi, C. L.; Kugler, J. W.; Sloan, J. A.; Mailliard, J. A.; LaVasseur, B. I.; Barton, D. L.; Novotny, P. J.; Dakhil, S. R.; Rodger, K.; Rummans, T. A.; Christensen, B. J. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial Lancet 2000, 356, 2059-2063
24. Pertovaara, A. Noradrenergic pain modulation Prog. Neurobiol. 2006, 80 (2) 53-83
25. Holden, J. E.; Schwartz, E. J.; Proudfit, H. K. Microinjection of morphine in the A7 catecholamine cell group produces opposing effects on nociception that are mediated by alpha 1-and alpha 2-adrenoceptors Neuroscience 1999, 91, 979-990
26. Ren, K.; Dubner, R. Descending modulation in persistent pain: an update Pain 2002, 100, 1-6
27. Ren, K.; Ruda, M. A. Descending modulation of Fos expression after persistent peripheral inflammation NeuroReport 1996, 7, 2186-2190 (Pubitemid 26361843)
28. D'Amour, F. E.; Smith, D. L. A method for determining loss of pain sensation J. Pharm. Exp. Ther. 1941, 72, 74-79
29. Valenzano, K. J.; Tafesse, L.; Lee, G.; Harrison, J. E.; Boulet, J. M.; Gottshall, S. L.; Mark, L.; Pearson, M. S.; Miller, W.; Shan, S.; Rabadi, L.; Rotshteyn, Y.; Chaffer, S. M.; Turchin, P. I.; Elsemore, D. A.; Toth, M.; Koetzner, L.; Whiteside, G. T. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia, and catalepsy Neuropharmacology 2005, 48, 658-672
30. Kim, S. H.; Chung, J. M. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat Pain 1992, 50, 355-363
31. Sullivan, N. R.; Leventhal, L.; Harrison, J.; Smith, V. A.; Cummons, T. A.; Spangler, T. B.; Sun, S.-C. L., P.; Uveges, A. J.; Strassle, B. W.; Piesla, M. J.; Ramdass, R.; Barry, A.; Schantz, J.; Adams, W.; Whiteside, G. T.; Adedoyin, A.; Jones, P. G. Pharmacological characterization of the muscarinic agonist (3 R,4 R)-3-(3-hexylsulfanyl-pyrazin-2-yloxy)-1-azabicyclo[2.2.1]heptane (WAY-132983) in in vitro and in vivo models of chronic pain J. Pharmacol. Exp. Ther. 2007, 322, 1294-1304